Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

52.91 +0.92 (+1.77%)

Streaming Delayed Price Updated: 2:22 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9

...

44 45 Next >

Why Moderna Stock Has Surged 20% This Week Despite Mixed News ↗

March 07, 2025

Recent news has been mixed with a patent win and loss in Germany and the U.S. But Moderna stock has risen markedly this week.

Via Investor's Business Daily

Topics Intellectual Property

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251 ↗

March 06, 2025

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves.

Via Benzinga

Topics Earnings

GSK's Once-Daily Inhalers For Smoker's Lung Has Potential Benefits: Independent Organization Report ↗

March 04, 2025

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

Via Benzinga

GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review ↗

March 03, 2025

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements.

Via Benzinga

Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis ↗

March 03, 2025

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Via Benzinga

Peering Into GSK's Recent Short Interest ↗

February 24, 2025

Via Benzinga

Bear Of The Day: Gsk Plc ↗

February 06, 2025

GSK PLC is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported.

Via Talk Markets

Topics Stocks / Equities

Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds ↗

February 27, 2025

Moderna is under pressure as two of its vaccines hit potential snags.

Via Investor's Business Daily

Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025 ↗

February 27, 2025

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.

Via Benzinga

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK

February 25, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week ↗

February 18, 2025

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage recommendations on Feb. 26.

Via Benzinga

GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 17, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors ↗

February 17, 2025

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.

Via Benzinga

PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY

February 17, 2025

From GSK plc

Via Business Wire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK

February 16, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK

February 13, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Deadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

February 12, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty ↗

February 11, 2025

Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.

Via Benzinga

Deadline Approaching: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

February 11, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Law Offices of Frank R. Cruz Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action

February 11, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action

February 10, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Merck: 4 No-Brainer Reasons to Buy This Dip

February 10, 2025

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

Via MarketBeat

Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch ↗

February 10, 2025

A Nevada dairy worker who initially tested positive for bird flu is currently experiencing mild symptoms, including "pink eye."

Via Benzinga

GSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 09, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Law Offices of Howard G. Smith Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action

February 07, 2025

From Law Offices of Howard G. Smith

Via Business Wire

GSK PLC Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against GSK

February 06, 2025

From Robbins LLP

Via GlobeNewswire

GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm

February 06, 2025

From The Schall Law Firm

Via Business Wire

Securities Fraud Investigation Into GSK plc. (GSK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

February 06, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

GSK plc. (GSK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

February 05, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Large Losses to Contact the Firm for Information About Their Rights

February 05, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.